PSE
27.4.2021 16:36:05 CEST | Business Wire | Press release
Process Systems Enterprise (PSE), A Siemens Business, today announced the full release of gPROMS FormulatedProducts 2.0, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005797/en/
The release at the 2021 Advanced Process Modelling Forum follows an early release to key customers, and reflects the substantial investment Siemens is making into PSE’s product development to provide the process industries with a new generation of digital tools.
Version 2.0 introduces major enhancements to both the gPROMS FormulatedProducts model libraries and the underlying gPROMS platform 7.0, such as surrogate modelling. Additions include new mechanistic model libraries for developing bioprocess digital twins of bioreactor, membrane filtration and chromatography processes, and a new mechanistic canine model for the design, virtual formulation prototyping and risk analysis of clinical and pre-clinical drug product formulations.
Version 2.0 also introduces key library enhancements in active ingredient manufacture, formulation manufacture and product performance. Workflows when specifying buffers and media compositions of in vitro vessel, solution and suspension dosage forms have been streamlined, and equilibrium limited reactions added to the chemical synthesis libraries. Additionally, this release includes many usability and robustness enhancements to provide an improved user experience, such as a new case file structure, streamlined data import workflows using a new experiment data manager, parallel multi-start optimization and parameter estimation, and new cross-disciplinary examples and templates that can directly be customised to users’ projects.
Sean Bermingham, VP Formulated Products at PSE, says: “We are working closely with our major users in pharma, F&B, FMCG, specialty chemicals and mining, with their requirements driving our extensive development programme. Our focus is now in extending usability and the ability to embed gPROMS FormulatedProducts in organisations’ workflows to open the application of sophisticated digital design approaches to a wider range of users, and the Siemens investments are allowing us to move forward rapidly.”
PSE continues to lead innovation in advanced process modelling capabilities for the pharmaceuticals, food & beverage, consumer goods and specialty chemicals sectors through the support of industrial & academic partners, funded development projects such as NextGen DDaMM, D-DAP, DIDCOM-FP, and the Systems-based Pharmaceutics Alliance.
For editors
‘About’: www.psenterprise.com/news
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005797/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Launches Cash Tender Offer28.9.2026 13:21:00 CEST | Press release
THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES (the “Offeror”) announces today that it is inviting holders of its outstanding €500,000,000 0.875 per cent. Guaranteed Notes
Horizon3 Earns Cyber Essentials Certification Covering NodeZero EU Network28.9.2026 10:00:00 CEST | Press release
Certification provides a defined security baseline for the network supporting Horizon3’s EU data sovereignty site in Germany Horizon3, the AI-Native Proactive Security Company, today announced that it has earned Cyber Essentials Plus certification covering its NodeZero AWS EU network. The network supports Horizon3’s EU data sovereignty site in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928143792/en/ Horizon3 Earns Cyber Essentials Certification Covering NodeZero EU Network Organizations use NodeZero® to test production environments and find weaknesses attackers can exploit. When customers and partners assess the platform itself, they also need to understand the security standards applied to its supporting infrastructure. The Cyber Essentials certificate identifies a defined portion of that infrastructure and the baseline against which it was assessed. Developed by the UK’s National Cyber Security Centre, Cybe
Thales Expands Collaboration with Google Cloud to Help Secure Agentic AI Workflows28.9.2026 09:03:00 CEST | Press release
Integration enables new protections for communications between AI agents, models, enterprise data, and tools to help control what agents can access, share, and do Thales AI Security Fabric mitigates risks, brings enhanced visibility and policy enforcement to AI-driven workflows on Google Cloud Thales today announced an expanded collaboration with Google Cloud to help enterprises address emerging security and governance challenges associated with agentic AI, bringing integrated protection, visibility, and policy enforcement to AI-driven workflows on Google Cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928647188/en/ ©Thales The integration of Thales AI Security Fabric with Google Cloud Gemini Enterprise helps organizations apply security, governance, and visibility across interactions among users, agents, models, and tools in real time. “Enterprises are moving from AI assistants to AI agents that can autonomously ta
SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP Fines28.9.2026 08:13:00 CEST | Press release
British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance. As the European Medicines Agency advances structured medicinal product data, companies face pressure to keep regulatory data accurate, standardised and aligned with EMA requirements. SPORVIGILANCE replaces fragmented manual assessment with a regulatory intelligence layer built around IDMP, SPOR and Product Management Service (PMS) requirements. At its core is an IDMP Business Rule Validation Engine that assesses medicinal product data at scale and at field level, identifying missing, inconsistent and non-compliant data. SPORVIGILANCE is the only platform to translate IDMP business rules directly into automated validation logic, enabling companies to test data against the rules rather than rely on manual interpretation. Its PMS Alignment capability reconciles internal RIM data ag
Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech Companies28.9.2026 08:00:00 CEST | Press release
The new fund extends Sofinnova’s 20-year track record of company creation with capacity to launch six to eight new ventures across Europe and the US Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand Sofinnova's medtech company-creation strategy across Europe and the US with greater capacity to launch new ventures and support them through key stages of development. With plans to launch six to eight new medtech companies over the next five years, Sofinnova MD Start IV will support ventures from inception through key clinical and operational milestones, providing founders with both capital and hands-on support. Sofinnova MD Start's approach combines clinical insight, entrepreneurial talent, and operational expertise to tackle significant unmet medical needs. The previous fund, Sofinnova MD Sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom